Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Regulatory press release

PEPTONIC Medical AB: PEPTONIC medical AB presents proposals for board members ahead of the annual general meeting on 26 June 2025

Peptonic Medical
Read the release

On 23 May 2025, PEPTONIC medical AB ("Peptonic" or the "Company") issued a notice to the annual general meeting to be held on 26 June 2025. The notice to the annual general meeting proposed that the board of directors should consist of four (4) ordinary board members without deputies and that the nomination committee intended to present proposals for board members as soon as possible. In light of this, the Company is publishing the nomination committee's proposals for board members.

Item 11 - Election of board members and any deputy board members

The nomination committee proposes that Anders Blom, Jacob Eriksson, Daniel Rudeklint, and Tarek Shoeb, be re-elected as board members for the period until the end of the next annual general meeting. Anders Blom is proposed for re-election as chairman of the board.

For further information, please contact:
Anna Linton, CEO, Peptonic Medical AB
Email: anna.linton@peptonicmedical.se                             
Phone: +46 70-244 92 07

About Peptonic Medical AB                                                                                                       
PEPTONIC medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women's intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic's growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.

The Company is headquartered in Stockholm, Sweden, and operates the subsidiaries, Peptonic Medical Inc. and Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.